Deals
The Novartis CEO believes the west has much to learn, especially in terms of clinical trial regulations and enrolment.
Henlius planning Japanese NDA by end of March 2027 for ES-SCLC and development in several other indications.
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
With Skyrizi and Rinvoq expected to anchor growth this decade, AbbVie said it will look at big and small assets to help it deliver revenue growth during the 2030s.
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Bristol Myers Squibb execs David Elkins and Adam Lenkowsky spoke with Scrip about the company’s efforts to grow new products and advance novel drugs before Opdivo and Eliquis lose exclusivity in 2028.
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Rocatinlimab has met primary endpoints in Phase III studies, but analysts question the Kyowa-discovered drug’s market potential due to tolerability and unspectacular efficacy.
UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.
Plus deals involving Insilico/Qilu, Insilico/Hygtia, AstraZeneca/AbelZeta, Alteogen/Tesaro, Ellipses/Innolake and more.
Scrip spoke with Novo’s SVPs for global research and global business development, Jacob Petersen and Tamara Darsow, about dealmaking and R&D priorities after the company streamlined to focus more intensely on obesity and diabetes.
Deal Snapshot: Following alliances with BMS, Genentech and Pfizer, Repertoire is partnering with Lilly to discover T-cell targeted autoimmune therapies. Deal continues a busy January for Lilly’s business development.
Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.
The US giant could pay up to $1.12bn to the German biotech after getting access to its programmable recombinase technology.
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
Plus deals involving Alfasigma/Innovative Molecules, Genethon/AskBio, XTL/NeuroNOS, ESTEVE/TerSera, Tahoe/Alloy, Bayer/Attralus and more.
Deal Snapshot: The German group is the latest big pharma to partner with one of China's most prolific dealmakers in an agreement that could be worth over $1bn.